HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys

A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown delay or prevention of viral rebound following ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Moldt, Brian, Chandrashekar, Abishek, Borducchi, Erica N., Nkolola, Joseph P., Stephenson, Heather, Nagel, Mark, Hung, Magdeleine, Goldsmith, Joshua, Pace, Craig S., Carr, Brian, Thomsen, Nathan D., Blair, Wade S., Geleziunas, Romas, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067686/
https://www.ncbi.nlm.nih.gov/pubmed/35452496
http://dx.doi.org/10.1371/journal.ppat.1010467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067686/
https://www.ncbi.nlm.nih.gov/pubmed/35452496
http://dx.doi.org/10.1371/journal.ppat.1010467

Ejemplares similares